MOGAT3: A Potential Drug Target Or Biomarker for Diseases (G346606)

Target Name: MOGAT3

NCBI ID: G346606

MOGAT3

MOGAT3: A Potential Drug Target Or Biomarker for Diseases

MOGAT3, or acyl-coenzyme A:monoacylglycerol acyltransferase 3, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. The MOGAT3 gene is located on chromosome 12 and encodes a protein that is involved in the metabolism of fatty acids, which is critical for maintaining cellular health and function.

The MOGAT3 gene was first identified in 2008 as a potential drug target due to its involvement in the regulation of lipid metabolism. The MOGAT3 protein is known to play a role in the transport of fatty acids into mitochondria, where they can be used for energy production. MOGAT3 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth and differentiation.

In addition to its potential drug-target properties, MOGAT3 has also been shown to be a potential biomarker for several diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. For example, MOGAT3 has been shown to be expressed increased in individuals with type 2 diabetes, and has been used as a diagnostic marker for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

One of the challenges in studying MOGAT3 is its prevalence in the population, as it is a relatively rare gene. However, research is ongoing to better understand the role of MOGAT3 in disease and to identify potential drug targets or biomarkers.

In conclusion, MOGAT3 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand its role in disease and to identify its potential as a drug or biomarker.

Protein Name: Monoacylglycerol O-acyltransferase 3

Functions: Catalyzes the formation of diacylglycerol from 2-monoacylglycerol and fatty acyl-CoA. Also able to catalyze the terminal step in triacylglycerol synthesis by using diacylglycerol and fatty acyl-CoA as substrates. Has a preference toward palmitoyl-CoA and oleoyl-CoA. May be involved in absorption of dietary fat in the small intestine by catalyzing the resynthesis of triacylglycerol in enterocytes. Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705)

The "MOGAT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOGAT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets